Special Look at Phase 1b Imvax Study to Assess the Safety & Efficacy of IGV-001

• Explore highest exposure cohort yielded significantly higher pro- inflammatory cytokine serum levels significant improvement
  in both PFS and OS over historical controls
• Study methylated subgroup manifesting a 3-fold improvement in mPFS with mOS not yet reached
• Deep dive with data lock, highest exposure cohort exhibiting significant improvement in both PFS and OS over
  historical controls

An Overview of Emerging Therapeutic Targets

• Examine the current treatment options and emerging targeted therapies
• If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit
  to GBM patients?
• Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?